Matsumoto Toshihiko, Ozaki Shigeru, Kobayashi Ohji, Wada Kiyoshi
National Institute of Mental Health, National Center of Neurology and Psychiatry.
Seishin Shinkeigaku Zasshi. 2011;113(12):1184-98.
The purpose of the present study was to examine the current situation regarding sedative (mainly benzodiazepines)-related disorder in Japan and the clinical characteristics of Japanese patients with this disorder.
Subjects were 671 drug-related disorder patients diagnosed according to the ICD-10 classification as "F1: mental and behavioural disorders due to psychoactive substance use," who abused psychoactive substances other than alcohol. Of all the psychiatric hospitals in Japan between September and October 2010, these drug-related disorder patients had consecutively consulted or were admitted to 153 psychiatric hospitals.
The present study was conducted by means of a mail survey. Subjects' clinical information, including history of psychoactive substance use, means of access to the primary drug of abuse, other ICD-10 diagnoses including the F1 subcategory and comorbid psychiatric disorders, and recent history of self-destructive behavior, were collected from the attending psychiatrists of each subject. The data thus gathered concerning sedative-related disorder patients were compared with those of patients with methamphetamine-related disorder, which has been the most serious drug-related problem in Japan since the 1950s.
Out of the 671 subjects, 119 patients mainly abusing sedatives (SRD group) were identified, while 361 patients were identified as mainly abusing methamphetamine (MRD group). The MRD group was the largest population (53.8% of the total subjects), followed by the SRD group (17.7%), and then the inhalant-related disorder group with 56 patients (8. 3%). Compared with the MRD group, the SRD group was younger, contained more female patients, and had a lower incidence of a history of involvement with anti-social societies and anti-social behavior. Patients in the SRD group were more likely to have started abusing drugs with the intention of reducing the unpleasant symptoms of insomnia (42.9%), anxiety (26.1%), and depression (16.0%), and to acquire the drugs they abused from medical institutions such as psychiatric or primary care clinics (82.1%), while patients in the MRD group were more likely to have started out of curiosity (35.1%) or in response to peer pressure (47. 1%), and to acquire their drugs from a "pusher" (32.8%). Additionally, in the SRD group, the ICD-10 F1 subcategory diagnoses that were the clinically most important were "dependence syndrome" (64.0%), "harmful use" (16.2%), and "acute intoxication" (16.2%), while the most important subcategory diagnosis in the MRD group was "psychotic disorder" (34.3%) and "residual disorder and late-onset psychotic disorder" (32.9%). Further, comorbid psychiatric disorders were more frequently found in the SRD group than in the MRD group; notably, co-occurrence of mood disorder was found in 45.0% of the SRD group in contrast to the MRD group (11.9%). Recent episodes of deliberate self-harm behavior were also more frequently found in the SRD group than the MRD group (33.6 vs. 10.5%, respectively) ; the major means by which these patients harmed themselves was by overdosing on prescribed drugs (23.5 vs. 4.7%, respectively).
The present study suggests that sedative-related disorder is an important clinical issue in the field of drug-related disorders in Japan today, and that SRD patients may represent a distinct type of drug abuser whose clinical characteristics are different from those of MRD patients. The development and spread of treatment programs for "dependence syndrome" and "harmful use" will help SRD patients, and educating psychiatrists about SRD will help prevent future sedative abuse.
本研究旨在调查日本镇静剂(主要是苯二氮卓类药物)相关障碍的现状以及患有该障碍的日本患者的临床特征。
研究对象为671名根据国际疾病分类第10版(ICD - 10)分类诊断为“F1:精神活性物质所致精神和行为障碍”且滥用酒精以外精神活性物质的药物相关障碍患者。在2010年9月至10月期间,日本所有精神病院中,这些药物相关障碍患者连续就诊或入住了153家精神病院。
本研究通过邮寄调查的方式进行。从每位研究对象的主治精神科医生处收集研究对象的临床信息,包括精神活性物质使用史、获取主要滥用药物的途径、其他ICD - 10诊断(包括F1亚类)以及共病的精神障碍,还有近期的自我毁灭行为史。将收集到的有关镇静剂相关障碍患者的数据与甲基苯丙胺相关障碍患者的数据进行比较,自20世纪50年代以来,甲基苯丙胺相关障碍一直是日本最严重的药物相关问题。
在671名研究对象中,确定了119名主要滥用镇静剂的患者(SRD组),同时确定了361名主要滥用甲基苯丙胺的患者(MRD组)。MRD组人数最多(占总研究对象的53.8%),其次是SRD组(17.7%),然后是吸入剂相关障碍组,有56名患者(8.3%)。与MRD组相比,SRD组患者更年轻,女性患者更多,有反社会社团参与史和反社会行为的发生率更低。SRD组患者更倾向于为减轻失眠(42.9%)、焦虑(26.1%)和抑郁(16.0%)等不适症状而开始滥用药物,并且更倾向于从精神病科或初级保健诊所等医疗机构获取他们滥用的药物(82.1%),而MRD组患者更倾向于出于好奇(35.1%)或受同伴压力(47.1%)而开始滥用药物,并且从“毒贩”处获取药物(32.8%)。此外,在SRD组中,临床上最重要的ICD - 10 F1亚类诊断是“依赖综合征”(64.0%)、“有害使用”(16.2%)和“急性中毒”(16.2%),而MRD组中最重要的亚类诊断是“精神障碍”(34.3%)和“残留障碍及迟发性精神障碍”(32.9%)。此外,SRD组共病精神障碍的发生率高于MRD组;值得注意的是,SRD组中有45.0%出现情绪障碍共病,而MRD组为11.9%。近期故意自我伤害行为在SRD组中的发生率也高于MRD组(分别为33.6%和10.5%);这些患者自我伤害的主要方式是过量服用处方药(分别为23.5%和4.7%)。
本研究表明,镇静剂相关障碍是当今日本药物相关障碍领域中的一个重要临床问题,并且SRD患者可能代表一种独特类型的药物滥用者,其临床特征与MRD患者不同。针对“依赖综合征”和“有害使用”的治疗方案的开发和推广将有助于SRD患者,并且对精神科医生进行关于SRD的教育将有助于预防未来的镇静剂滥用。